NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis $20.85 +1.01 (+5.09%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$20.88 +0.03 (+0.14%) As of 08/22/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enliven Therapeutics Stock (NASDAQ:ELVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enliven Therapeutics alerts:Sign Up Key Stats Today's Range$19.62▼$21.0750-Day Range$17.69▼$23.3452-Week Range$13.30▼$30.03Volume830,394 shsAverage Volume362,165 shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$41.20Consensus RatingBuy Company Overview Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado. Read More Enliven Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreELVN MarketRank™: Enliven Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 459th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEnliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnliven Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Enliven Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.95) to ($2.35) per share.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.93% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently decreased by 8.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.93% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently decreased by 8.30%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.34 News SentimentEnliven Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Enliven Therapeutics this week, compared to 4 articles on an average week.Search Interest2 people have searched for ELVN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,472,368.00 in company stock.Percentage Held by Insiders25.90% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enliven Therapeutics' insider trading history. Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ELVN Stock News HeadlinesInsider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells 5,000 Shares of StockAugust 22 at 8:42 AM | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) CEO Sells $11,800.00 in StockAugust 21 at 9:20 AM | insidertrades.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 23 at 2:00 AM | Crypto 101 Media (Ad)Lifesci Capital Has Positive Outlook for ELVN Q3 EarningsAugust 18, 2025 | americanbankingnews.comWe're Not Very Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn RateAugust 15, 2025 | finance.yahoo.comEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateAugust 14, 2025 | finanznachrichten.deEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateAugust 13, 2025 | prnewswire.comEnliven Therapeutics Inc. Stock Grades | ELVN | Barron'sAugust 12, 2025 | barrons.comSee More Headlines ELVN Stock Analysis - Frequently Asked Questions How have ELVN shares performed this year? Enliven Therapeutics' stock was trading at $22.50 on January 1st, 2025. Since then, ELVN shares have decreased by 7.3% and is now trading at $20.85. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) announced its earnings results on Wednesday, August, 13th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. Who are Enliven Therapeutics' major shareholders? Top institutional investors of Enliven Therapeutics include Commodore Capital LP (9.56%), Geode Capital Management LLC (1.80%), 5AM Venture Management LLC (1.57%) and TCG Crossover Management LLC (1.01%). Insiders that own company stock include Joseph P Lyssikatos, Samuel Kintz, 5Am Partners Vi, Llc, Anish Patel, Rishi Gupta, Richard A Heyman, Benjamin Hohl and Rahul D Ballal. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enliven Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/13/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELVN CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Enliven Therapeutics$41.20 High Price Target$52.00 Low Price Target$27.00 Potential Upside/Downside+97.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.02 million Net MarginsN/A Pretax MarginN/A Return on Equity-29.15% Return on Assets-27.88% Debt Debt-to-Equity RatioN/A Current Ratio32.58 Quick Ratio32.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.25 per share Price / Book2.53Miscellaneous Outstanding Shares59,240,000Free Float43,894,000Market Cap$1.24 billion OptionableOptionable Beta0.93 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ELVN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.